skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Paliperidone ER: a review of the clinical trial data

Review

(2793) Views  (982) Full article downloads

Authors: Philip G Janicak, Elizabeth A Winans

Published Date January 2007 Volume 2007:3(6) Pages 869 - 883
DOI: http://dx.doi.org/10.2147/NDT.S1365

Philip G Janicak1, Elizabeth A Winans2,3

1Department of Psychiatry, Rush University Medical Center, Chicago, IL, USA; 2Previously Employed by Scientific Affairs, Ortho-McNeil Janssen, LLC, Chicago, IL, USA; 3Department of Pharmacy Practice, University of Missouri Kansas City, MO, USA

Abstract: Paliperidone extended-release tablet (paliperidone ER; INVEGATM) is an oral antipsychotic for the treatment of schizophrenia. The recommended dose range is 3–12 mg per day. Paliperidone ER utilizes the OROS® delivery system, which allows for once-daily dosing. Its pharmacokinetic profile results in a more stable serum concentration. Paliperidone is 9-hydroxyrisperidone, the chief active metabolite of risperidone. It undergoes limited hepatic metabolism, thereby minimizing the risks of hepatic drug–drug and drug–disease interactions. Three 6-week trials in patients with acute schizophrenia reported that paliperidone ER was effective, well tolerated, and produced clinically meaningful improvements in personal and social functioning compared with placebo. Post-hoc analysis of these trials in various populations, including recently diagnosed, elderly and more severely ill patients, those with sleep disturbances and those with predominant negative symptoms demonstrated improvement as well. Paliperidone ER was also significantly better than placebo in the prevention of symptom recurrence in a 6-month maintenance study. The most common clinically relevant adverse events associated with paliperidone ER were extrapyramidal symptoms, tachycardia and somnolence. The incidence of Parkinsonism, akathisia and use of anticholinergic medications increased in a dose-related manner. Further, modest QTc interval prolongation was observed but did not produce clinical symptoms. Similar to risperidone, paliperidone ER is associated with increases in serum prolactin levels. Overall, paliperidone ER was effective, well tolerated and provides a new treatment option for patients with schizophrenia.

Keywords: paliperidone, extended-release, antipsychotic, schizophrenia








Readers of this article also read:

Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER
"If we only got a chance.” Barriers to and possibilities for a more health-promoting health service
Levels of circulating homocysteine, vitamin B6, vitamin B12, and folate in different types of open-angle glaucoma
Traditional and new strategies in the primary prevention of eating disorders: a comparative study in Spanish adolescents
Once-monthly paliperidone injection for the treatment of schizophrenia
Role of paliperidone extended-release in treatment of schizoaffective disorder
Obesity and respiratory diseases
Reorientation to more health promotion in health services – a study of barriers and possibilities from the perspective of health professionals
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
Paliperidone extended-release: does it have a place in antipsychotic therapy?